Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

Development and Use of a Population Pharmacokinetic Model of Amikacin and Vancomycin for the Optimization of Dosing Regimens in Critically Ill Patients on Different Modalities of Extracorporeal Hemoadsorption

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Inclusion Criteria:

• diagnosis of SIRS, sepsis and/or septic shock,
• older than 18 years, who are being treated with amikacin and/or vancomycin,
• length of use of adsorbent at least 12 hours.

Exclusion Criteria:

• contraindication for hemodiafiltration with adsorbents,
• patients under the age of 18,
• terminal cancer patients.